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Residualizing labels for protein, such as dilactitol- DLT)' (3), and cellobiitol-"51-tyramine (4), have been used
'261-tyramine (lZ6I-DLT) and
cellobiitol-'261-tyramine, to identify the tissue andcellular sites of catabolism of plasma
have been used to identifythe tissue and cellular sites proteins, such as albumin (5-7), lipoproteins (4, 8),and imof catabolism of long-lived plasma proteins, such as munoglobulins (9), and are also being increasingly used in
albumin, immunoglobulins, and lipoproteins. The ra- studies on the uptake and catabolism of proteins by cells in
dioactive degradation products formed from labeled culture (8, 10). One of the limitations of the use of these
proteins are relatively large, hydrophilic, resistant to labels, however, is that whereas their rate of loss from cells is
lysosomal hydrolases, and accumulate in lysosomes in slow ( t ~ 2 days for '251-DLT in rat tissues), the rates of
the cells involved in degradationof the carrierprotein. catabolism of plasma proteins areoften equally slow or slower.
However, the gradualloss of the catabolites fromcells
Thus, a substantial fraction of degradation products is lost
( t n 2 days) has limited the usefulness of residualizing
labels in studies on longer lived proteins. We describe from tissues by the time significant amounts of the protein
here a higher molecular weight (Mr 5000),more have been catabolized. Under these circumstances, it is not
efficientresidualizing glycoconjugate label, inulin- possible to assess rigorously the quantitative role of various
'261-tyramine (lZ6I-InTn).Attachment of "'1-InTn had tissues in catabolism of a protein since the distribution of
no effect on the plasma half-life or tissue sites of catab- degradation products in the body could be biased by differolism of asialofetuin, fetuin, or rat serum albumin in ences in the rate of loss of the label from various cell types.
Because of the limited residualization of tetrasaccharide
the rat.The half-life for hepatic retention
of degradation products from '261-InTn-labeledasialofetuin was derivatives of tyramine and the fact that residualization is
5 days, compared to 2.3 daysfor '261-DLT-labeled improved with increasing saccharide contentor molecular
asialofetuin. The whole bodyhalf-lives for radioactiv- weight of the label (3), we set outto design a higher molecular
ity from '261-InTn-, "'1-DLT-, and '261-labeled rat weight oligosaccharidederivative of tyramine, with the expecserum albumin were 7.5, 4.3, and 2.2 days, respec- tation that this label would be retained more efficiently in
tively. The tissue distribution of degradation products cells. Wedescribe here the biological properties of in~lin-"~Ifrom '261-InTn-labeledproteins agreed with resultsof tyramine ( lZ5I-InTn), aresidualizing glycoconjugate label deprevious studies using lZ6I-DLT,except that a greater rived from the inert fructan polymer inulin ( M , 5000). The
fraction of total degradation products was recovered retention of protein degradation products containingthe 1251in tissues. Kinetic analyses indicatedthat the average InTn label results from both their size and the absence of
half-life for retention of lZ6I-InTn degradation prod- lysosomal fructofuranosidase activity (11).As shown below,
ucts in tissues is -5 days and suggested that in vivo lZ5I-InTn,the largest residualizing label for protein described
there are both slow and rapid routes for release of thus far, has negligible effects on the kinetics or tissue sites
degradation products fromcells. Overall, these experiments indicate that '261-InTn should provide greater of plasma protein catabolism and is retained in lysosomes
sensitivity andmore accurate quantitative informationmore efficiently than is lz5I-DLT.The data indicate that lz5Ion the sitesof catabolism of long-lived circulating pro- InTn should be widelyapplicable in studies on the catabolism
of long-lived circulating proteins.
teins in vivo.
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-
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EXPERIMENTAL PROCEDURES AND RESULTS'

Residualking labels are biologically inert radioactive tags
used for studies on the sites of protein catabolism in uiuo.
These labels are designed to yield limit, hydrophilic degradation products of a sufficient size that they are retained in
lysosomes following catabolism of the carrier protein. The
sites of degradation of the labeled. protein may then be determined either by measuring acid-soluble radioactivity in various tissues and cells or by autoradiography. Residualizing
labels, such as [3H]raffin~~e
(2), dilactitol-"51-tyramine (lZ5I-

* This work was supported by National Institutes of Health Research Grant DK 25373. A preliminary report of this work has been
presented (1).The costs of publication of this article were defrayed
in part by the payment of page charges. This article must therefore
be hereby marked "aduertisement" in accordance with 18 U.S.C.
Section 1734 solely to indicate this fact.
T To whom correspondence should be addressed.

The chemistry of synthesis and coupling of lZ5I-InTnto
protein is outlined in Fig. 1 and described in detail under
"Experimental Procedures." Also described in the Miniprint
are a series of preliminary experiments validating the usefulness of InTn in studies on catabolism of circulating proteins
such as asialofetuin and fetuin. The effectiveness of InTn as
a residualizing label is clearly illustrated in Fig. 5, which
shows both the plasma and whole body kinetics of clearance
of Iz5I-, lz5I-DLT-, and "51-InTn-labeled RSA. Notably, as
The abbreviations used are: lZ5I-DLT,dila~titol-~~~I-tyramine;
lz5IInTN, in~lin-'~~I-tyrarnine;
RSA, rat serum albumin; *I, lZ5I.
* Portions of this paper (including "Experimental Procedures," part
of "Results," Figs, 2-4 and 6, and Tables 1-111) are presented in
miniprint at the end of this paper. Miniprint is easily read with the
aid of a standard magnifying glass. Full size photocopies are included
in the microfilm edition of the Journal that is available from Waverly
Press.
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INULIFI-O-CHz

FIG. 1. Reaction scheme for synthesis of lZSI-InTnand its coupling
toprotein.
Inulin is reduced with
NaBH4, and the terminal alditol is oxidized with a limiting amount of periodate
to generate an aldehyde. Tyramine is
coupled to inulin aldehyde by reductive
amination using NaBH3CN, yielding
InTn. InTn is then labeled with radioactive iodine using IODO-GEN and coupled to protein using cyanuric chloride.
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with asialofetuin and fetuin, the plasma half-life of RSA was
unaffected by the attachment of InTn. The lZ5I-InTndegradation products also residualized more efficiently, with a
whole body half-life of about 7.5 days, compared to 4-5 days
for lZ5I-DLT(Fig. 5 and Ref. 7). The tissue distribution of
radioactivity at 4 days after injection of '251-InTn-labeled
RSA, shown in Table 11, confirms previous evidence using
lZ5I-DLT-labeledRSA that catabolism ofRSA takes place
primarily in muscle and skin (7). However, in these experiments, a significantly greater fraction of total degradation
products was retained in the body. Thus, thecirculating halflife of this preparation of '251-InTn-labeledRSA was 1.8days,
i.e. 79% catabolism a t 4 days; the loss of 27% of radioactivity
from the body by 4 days indicates that about 66% (2779) of
the theoretical yield of '251-InTn-labeled RSA degradation
products was recovered, compared to 45% for '"I-DLT-labeled RSA (7). Overall, with all three proteins studied, the
lZ5I-InTnlabel yielded results consistentwith previous studies
using other labels, but with substantially improved retention
of degradation products in the body.
Kinetic Modeling of Plasma Protein Catabolism-As a first
step toward understanding the biological behavior of residualizing labels, we have attempted to develop kinetic models
for quantitative comparison of the rates of loss of the various
labels from tissues. For thispurpose, we have used SCoP and
SCoPfit programs, which are simulation control and optimization programs developed for the IBM-PC/AT computer by
the National Biomedical Simulation Resource at Duke University (Durham, NC). SCoPgenerates a graphical simulation
of a kinetic process, given a series of differential equations
(the kinetic model) and specified kinetic constants. The
SCoPfit program accepts actual experimental data and, using
the SCoP model, develops kinetic constants to optimize the

fit of experimental data to the

model. For the purpose of
illustrating the results of calculations, experimental data from
Fig. 5 (lower) are replotted in Fig. 7, showing the kinetics of
whole body release of degradation products from lZ5I-DLTlabeled RSA (Fig. 7, upper) and '251-InTn-labeledRSA (Fig.
7, lower). The various lines drawn on the graph represent
different fits to the datausing the SCoP or SCoPfitprogram
with various models and assumptions, as described in detail
in the Miniprint. In summary, the dotted lines are derived
from the SCoP program using the three-compartment model
described in Fig. 6 and assuming that RSA degradation products leak from all tissues at thesame rate at which asialofetuin
degradation products leak from liver. Because of the poor fit
to the experimental data, SCoPfit was used with the same
model to optimize the kinetic constants and to improve the
fit to the data. However, this SCoPfit optimization (dashed
lines) was also unsatisfactory, and systematic error was apparent, suggesting that the model was inappropriate. Since
recent work byBuktenica et al. (30) indicated that degradation
products were routed throughboth slow andfast release
compartments in cells in vitro, the three-compartment model
was revised to allow for a fraction of degradation products to
be released rapidly from cells in vivo. The solid lines in Fig. 7
(upper and lower) are the results of SCoPfit optimizations to
this revised model and yield good and consistent fits to the
experimental data. The development, mathematical descriptionand assumptions, and the kinetic constants obtained
with the various models are described in detail in the Miniprint.
DISCUSSION

The need for residualizing labels which are more completely
retained in tissues has been apparent since the earliest experiments using this technology to identify the sites of plasma
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FIG. 5. Kinetics of plasma and wholebody clearance of
radioactivity from RSA labeled with 1261,1261-DLT,or IBIInTn. Upper, kinetics of clearance of RSA from the circulation.
Animals were injected with 10 X lo6 cprn (50-100 pg) of protein
labeled with 1261(0),I2'I-DLT (O), or lZ6I-InTn(A). Lower, kinetics
of whole body clearance of RSA. Animals were injected with 2.5 X
lo6 cpm of protein labeled with '''1 (0),Iz5I-DLT(O),or12'I-InTn

FIG. 7. Results of kinetic modeling to estimaterate of leakage of various labels from cells. The data are replotted from Fig.
5, bottom. The fitted lines are derived from equations described in
text, and kinetic constants are listed in Table 111.

decrease losses during handling, does not appear to interfere
with labeling of the protein, and is readily separated from
labeled protein by gelexclusion chromatography. In all of the
protein catabolism. Because of the gradual loss of degradation experiments described here, the average substitution of protein was limited to <1 mol of '261-InTn/mol of protein in
products from tissues, it has been necessary to terminate
experiments at times when only a fraction of the protein has order to decrease the probability of multiple derivatization of
been catabolized andthento
apply corrections for intact carrier proteins. The addition of 1 mol of 1261-InTn/molof
protein remaining in tissues, for example, by acid precipita- protein had no detectable effect on the kinetics, mechanisms,
tion of the intact protein (3, 7) or by injection of a second, or sites of catabolism of asialofetuin, fetuin, or RSA. This
result is consistent with recent hypotheses on the regulation
nonresidualizing tracer to estimate the amount of intact proof protein catabolism. Thus, thekinetics of protein catabolism
only
teinin the tissue (31). Thesemanipulationsarenot
appear to be determined by genetically encoded molecular
inconvenient, but they also ultimately affect the precision of features of the protein molecule, such as the amino-terminal
estimates of protein degradation in tissues. Our previous work amino acid or a sequence or array of amino acids in the
had revealed a relationship between the number of carbohy- primary or tertiary structure of the protein, rather than by
drate units in the label and its efficiency of residualization bulk physical characteristics such as hydrophobicity, subunit
(3), so that the synthesis of a larger glycoconjugate label molecular weight, or isoelectric point (32).
seemed a reasonable route for improving residualization.
The size of the radioactive products isolated from urine
There are obvious limits to this approach, however, since at using the [3H]raffinose (2), '261-DLT(3), or '261-InTN labels
some point the size or properties of the label itself will affect indicates that residualizing labels are excreted from the body
the mechanisms and sites of catabolism of the carrier protein. largely in intact form. Thus, following catabolism of the
An inulin derivative was chosen as areasonably sized target carrier protein,the labeled degradation products appearto be
since the resulting molecular weight of the label would be, at released from cells by the process of exocytosis or regurgitamost, about 10% of the mass of the smallest plasma protein. tion, rather than by deiodination or eventual hydrolysis to
The synthesis of InTn was straightforward, and itsiodination lower molecular weight products. The difference in whole
and coupling to protein proceeded with good efficiency, 30 body half-life of radioactivity from asialofetuin labeled with
and 70%, respectively. Thus, only nanomolar quantities are raffinose, DLT, InTn, andother labels (3) indicates that the
required to label proteins with high specific radioactivity. The structure of the label affects its rate of release from cells. In
inertness of underivatized inulin in the coupling reaction is addition, however, kinetic analysis indicates that there are
also convenient because this inulin serves asacarrier
to also differences in theroutes of transport of these indigestible
(A).
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compounds within the cell. Thus, whereas some residualization was observed with all of the labels, there was a fraction
of these labelsrapidlyreleasedfrom
the body so that a
significant lag phase in whole body clearance not
wasobserved
(Figs. 4 and 5, lower). Based on kinetic analysis, we have
concluded that degradation products may be partitioned between slow andfast release compartmentswithin the cell and
that routing of the partially degraded protein or labeled degradation productsto the fast release compartmentmay be an
important factor limiting the long-term retention of catabolites in the body. Our model makes no statement regarding
the natureof the fast releasecompartment,although it is
likely to be an early endocytic compartment, either prelysosoma1or inequilibrium with the lysosomalcompartment.
Whereas larger residualizing labels could theoretically prove
more efficient, there is greater risk that they will affect the
catabolism ofthe carrier protein. Formost purposes, the InTn
label should be suitable, for example, in studies on the catabolism of IgGs, which are among the longest lived circulating
proteins ( t H= 3-5 days in the rat).
Acknowledgment-We thank Thomas G. Huggins (Department of
Chemistry, University of South Carolina) for assistance in using the
SCoP and SCoPfit programs.
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Inulin-1251-Tyramine, an Improved Residualiring Label for Studies an
Sites Of Catabolism of Circulating Proteins
by Janet L. Maxwell. John Y . Baynes and Suzanne R. Thorpe
EXPERIUENTAL

PROCEDURES

stream Of nitrogen.
The pellet was redi&rolved in 1.25 ml 30 m
u imidaw l e , pH 6.5, a I-fold excess O f solid NaIO
added
and the mixture
stlrred at room temperature for 1 hl when a l l the &iodate
had been
consumed. based on assay for free periodate ( 1 8 ) .
The periodate treated
inulin
was
recovered
Iollowing
ethanol
precipitation
as
above,
immediately redissolved in 1.25 ml 0.1 U DOtassiUm borate.
7 ..”,
75
and
an 8-fold excess of solid tyramine added and the BOlYtion Stirred at room
temperature for 15 min to allow Schiff-base formation: a 100-fold excess
O f NaBH CN was then added and reductive amination carrlad out overnight
at room’tenperature with stirring. solid N ~ B H(25~:fold
exceee) vas then
added and the mixture let stand for another hour 1” order to reduce any
remaining oxidized qroups. Inulin and derivatives were precipitated with
ethanol and the pellet di8601ved in 0.1 N NaC1 and chromatographed on
Sephadex G-50 (Fig. 28).
Fractions containing InTn
(Fig. 28, fractions
25-33) were pooled, concentrated and desalted on Sephadex G-25 in n 0
The desalting step also removed any residual free tyramine and yieldea
final InTn preparation containing-0.2 mol tyramine/mol inulin.

.~

~

.

~~~

~

~

W s i s and Purification of I n : The scheme in Fig. 1 shows Our route
t o synthesis and iodination of InTn and coupling of *I-lnTn t o protein.
Inulin is generally described as a nan-reducingpolysaccharide
of
fructose linked t o a terminal sucr-o~e residue, however most commercial
preparations contain
a fraction of incomplete chains with
a redvcing
frVCtOse terminus ( 1 4 ) .
Sone enrichment for reducing inulin was obtained
by fractionating inulin on Sephadex G - 5 0 and pooling the fractions with
highest ratio Of reducingsugar, measured by the bicinchoninic acid a r r a y
115). to total sugar, measured by the anthrone assay
(16) (Fig. 211).
using fructose as standard in both assays.
The synthesis of InTn
was
carried With the enriched inulin pool (Fig. 21). using an adaptation of
the procedure Of Raja et a l , (17) for reductive amination Of hyaluronic
acid with aliphatic amines.
This procedure involves reduction
of the
terminal sugar Unit to an alditol, followed by limited oxidation with
periodate t o generate a reactivealdehydeterminus,
and reductive
amination of the polysaccharide with theamine.

Labelins of Inulin and IT&.
[3H1-inulin wan y e p a r e d by l d u c t i o n Of
fractionated inulin with 1 IO-fold excess of NaB H
as described above.
InTn was iodinated using methods described p r e v i d i y for the iodination
of DLT and other residualizing labela ( 3 ) .
Typically
InTn (lo m a l
based on tyramine absorbance at 220 nn) in 25 ul 0 . 5 N’potassiur. phorphate, pH 7.7, was Placed in a 0.5 1 1 polypropylene centrifuge tube
coated with 20 ug dried I d o g e n . Na*I, 1 mci in 10 u1 0.1 N NaOH
added and the iodination carried Out at room temperature for 20-30’m;::
The *I-InTn was isolated by cmntrifugal chroeatcqgrsphy on a 1 m l sephadex
6-25 (Phamacla) column in water (2 min in an IEC u d e l HN centrifuge at
900 rpm). when an aliquot Of the *I-InTn was added to carrier inulin (25
ag/ml), > 8 5 t at the radioactivity was precipitable by 8 0 1 ethanol.
The
efficiency Of iodination Was about 3 0 1 .
AS shown in Fig. 2C. +I-InTn
radioactivity eo-Chromatographed with total carbohydrate (added carrier)
On Sephadex G-50.

Reagent ratios in subsequent reactions are based on the Content of
reducing ends in the fractionated inulin preparation.
For a typical InTn
preparation, inulin (12 mg total inulin/ml, 1.16 unole reducing sugar/ml)
Vas dlSsolved in
0.1
POtllSS1Un borate, pH 8.3; oi 100-fold excess of
solid NaBH was added and the solution stirred for 4 h at room temperature.
Th% reaction vas quenched with 50 ul acetone, and 4 vo1umes of
ice cold ethanol were added (final concentration B o t ) t o precipitate
inulin and ite derivatives. The solution
was centrifuged in an IEC
Centra 7R centrifuge at 4 * C for 10 lnin at 2500 rpm, the =upernatant
discarded and residual ethanol removed from the precipitate under a

F o u ~ l i n a o f *I-InTn to D t&.
The procedure for the coupling
Of
tyramine derivatives t o protein using Cycl is similar to that described
previously ( 3 1 . FOT a typical labeling, * l - l n ~ n , 10 ”mol in I5 UI 0.15 I
Potassium phosphate. pH 7.7, was placed in a 0 . 5 m 1 polypropylene tube
and activated by additxon of a n equimolar amount Of Cycl in 4 u1 of
acetone.
After 30 SeS, protein. 2 mg ( 3 0 - 4 0 mol Of RSA or FET.
respectively) in 50-200 ul PBS vas added with wrtexing. TO estimate the
efficiency of coupling to protein, a 1 u 1 aliquot Of the reaction mixture
was removed after 5-10 min and
added t o carrier protein, 2 mg bovine
serum albumin (BSA) in 300 “1 H 0. then precipitated withan equal volume
of 40% trichloroacetic acid (TcK). Efficiency of couplinq was 50-701 tor

~

.
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the various protelns tested.The *I-InTn-plOteln was Separated from free
+I-InTn following dialysis and chromatography on Sephaicryl 5-200 as
*l-lnTn-aeialofetUin (*I-InTn-ASF) was
described
previously
(3).
Prepared by treatment Of *I-InTn-FET (10 mg/m1 0.1 n Na acetate, pH 5.2)
with one-half unit Of insolubilired neuraminidase far 4 h at 25 C. The
desialylated protein vas re-isolated by Chromatography on Sephacryl S-200
in PBS.
NO protein polymers were detected in these labeling experiments since
,958 of applied radioactivity was recovered in a single
D m t e i n band on SDS-PAGE.

In v i v o Exosiments. Experiments
were carried out in male and female
Sprague-Dawley rats, 130-220 9. Methods for animal care and maintenance,
iniectionOfDroteins.
and measurement Of ~ 1 a s m a and whole bod"
rahioastivity &e
bee" described previously (irl). Unless etheruise
indicated, a l l data points for plasma and whale body clearance curves are
averages for at least 3 animals and absence of error bars indicates that
the coefficient Of variation was 15%. Plasma Dind whole body half-lives
were estimated by linear regression analysis.
Total and acid Soluble
radioactivity in tissues were distinguished by precipitation with 2 0 % TCA
as described previously (3,7). In control experlnent *I-InTn. *I-lnTnor skin, and
PET or *I-InTn-RSA vas added t o nonradioactiveliver
processed for determination of acid Soluble radioactivity. Recoveries Of
soluble radioactivity were 94-91) far .I-InTn. and 3.9%
for *I-InTn-FET
and *I-InTn-RSA.
Subcellularfractionationof
liver by differential
centrifumation was nerformed accordinm t D Crerroriadis aind Sourkes 1191.

-.

Kinetics of plasma and whole body clearance Of radioactivity
following injection Of labeled ASF.
Of .I-IDTn-ASF
andcompetition
by E O injection of 2 mg unlabeled ASP. Animals were injected with 5 x 10' cpm
(-5ouq) of labeled protein.
Data points are average values for 2
animals in each experiment.
3 8 lbottoml: Kinetics Of whale body clearance Of radioactivity from ASF
labeled with *I (0). *I-DLT l a ) 0 *I-InTn (A). For each experiment
animals were injected with 2-3 x 1
0
' cpm (t50 us) labeled protein.

a:
Plasma clearance

Chromatographic characterization Of inulin Dind derivatives.
2h ItoDI:
1toDI:
Chromatography Of natural inulin.
Inulin (20 mg) was
dissolved in 2 1 1 0.2 w NaCl and chromatographed on a Sephadex G-50
column (1.5 x 47 Cn) in 0.2 M NDCI. Fractions. 2 ml. were collected and
assayed for total I*)and reducing (0) sugar as described in Haterials
and Eethcds.
Total sugar. measured as fructose, Was converted t o m o l
inulin assuming Mr.- 5 , 0 0 0 .
Fractions 24-33 (bracketed in figure) were
pooled for preparatlon of InTn.

In order to trace the disposition *I-lnTn
of
metabolites in liver.
animals were injected with .I-InTn-ASF and sacrificed at 1 h, 1, I and
d.
In a l l cases >90% of hepatic radioactivity Was in acid soluble
form. In addition, 92-95\ of radioactivity remaining in the body Was
recovered in the liver at all times: stomach, intestines their contents
accounted for a maximum of 2-3% of recovered radioactivity, indicating
minimal redistribution of the label into other tissues.
Animals Yere
also sacrificed at 1 h, 1 and 3 d after injection, and livers removed
nuclear mitoc~ondci.I-lys060~1 and Supernatant
and fractionated into
fractions (19). The recovery'of radioactiYitY in these fr.CtiDnB
Corresponded t o recovery of the lysosomal marker enzyme. beta-N-acetylhexosaminidase.
In a11 cases, <IO1 Of radioactivity and enzyme activity
were found in the post-lysosomal supernatant fraction, whereas
when
Intact *I-InTn-ASF was homogenized with liver and fractionated, 9 6 t of
the radioactivity. but only 12t of bet.-N-.cetylhexOs.minidaae
activity,
was recovered in the supernatant.
In general. the results
of these
experimentsWith
*I-InTn-ASF agreed Closely with Tflulte Obtained
.
* ! w]raffinose (2)
preVi4USly with Other residualiring labels, such e
and *I-DLT (3).
Thus, despite its sire, the attachment Of *I-InTn did
not detectably affect the uptake. compartmentation or catabolism Of S F
in liver.

28 (middle): Chromatoqraphy ofan 1nTn reaction mixture. After coupling
Of tyramine to inulin aldehyde, the ethanol precipitate was dissolved in
0.2 M NaCl and chromatographed as above.
Fractiona were assayed for
total carbohydrate ( 0 ) and tyramine by absorbance at 220 nm (A). Fract i m a 19-21 (bracketed in f l p r e ) were pooled for preparation of *I-InTn.
:
Chromatographic profile o f *I-InTn, prepared as described
I n Materials and Hethods.
Unlabeled carrier inulin was added t o obtain
the total carbohydrata profile( a ) .

Since *I-InTn-ASF was degraded to acid eolvble products in liver
within 1 h, the 1065 O f radioactivity from the whole body Yam used as oi
measure of the efficiency of residualization of the label. A comparison
of the whole body kinetics Of clearance of *I-ASF. *I-DLT-ASF and *IInTn-ASF is Shown in Fig. 3 %
The residualization of the InTn label
shows about a 2-fold improvement over that Of DLT, with hali-lives Of
2.3 and 5.1 d for the *I-DLT and *I-InTn degradation products. respectively.
The improvement in residualization with *I-lnTn is con6i6tent
molecular weightand
efficiency O f
withtherelationshipbetween
residualization observed in our previous Dtudies 13).

'5

-2,

dies With Mna-liv& proteins. The *I-InTn label Was next applied t0
%dies
on the catabolism of native fetuin. Fig. 4 shows that the whole
body half-life Of radioactivityfrom *I-FET is about 1 d, which itr equal
+n .
its
n"
a "
half-life
in the r a t 1 2 4 ) . while the wholebod" half-lives
" n l a c.
..~"
".
were 3-3.5 and 5-6 d for *I-DLT-FE< bid *I-InTn-FET, rerp;ctively. in
several experiments.Thetissuedistribution
of radioactivity was
determined. as described in Haterials and
nethod-. at 2 d (2 half-lives1
after injection of *I-DLT-FET and *I-InTn-FET. The overclll distribution
of radioactlvlty was similar in both cases (data not shown), with the
majority Of degradation product- being recovered in muscle and 3kin, in
agreement with earlier studies using the residualiring label, [ Hlraffincse (241.

__

RESULTS
-st~f C o u ~ l i n q 'I-InTn
to Proteb.
One c ~ n c e r n about caupling
residualiring labels t o protelnr in that the modificaeionO f the protein
may affectthebiologicalproperties
of the protein.
Tominimize
structural alterations in the protein the labeling reaction is normally
designed t o yield (1 mol labrl/mol protein in order t o decrease the
probability of modifying the ..am protein molecule twice. with the InTn
label there was also the possibility that the proteincould be modified
This seemed
by the 8 0 % inulin carrier in the *I-InTn preparation.
unlikely because Of the much higher pH required for reaction between
cycl aind carbohydrates (22). but the inertness of the carrier inulin was
also confirmed experimentally.
AS 6ho-n in Table I, CyCl coupling of
*f-I?Tn to 8SA proceeded with an efficiency of 1 0 % . compared t o < I %for
Cycl.
The results
are
[ H l m u l l n or in Control experiments without
consistent with our previous work indicating that CyCl couples *I-DLT to
protein via the tyramine moiety (3).
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Table I
Efficiency of couplinqof [3H]Inulln and *I-InTn to proteln
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[3H]lnulin
*I-Inulin-tyramine

&id-PresiDitable
Experimental
11)
70

W

v1
0

Radioactivit
.
O
"
t
,
$

0

e

1%)
<I
<I

V

W

Prepared as dfrcribed in $laterials and nethods.
Specific activities Were 7.1 X 10 Cpm/nmol I Hllnulin and 29 x IO6 cpm/nmol *I-InTn.
The specific radioactivity Of *I-InTn is based on its tyramine content,
i . e . . 0.2 nmol tyraminelnmol total inulin, thus IO nmol * ~ - l n ~contains
n
the equivalent oi 50 n n o ~total inulip.
Radioactive Compounds (50 nmOl ( ")inulin and I D nlOl *I-InTn) Were
activated with 10 "mol CyC1, reacted with BSA (2 mq, 30 nmol in 200 "1
phosphate buffer) and aliquots removed and assayed for acid preclpitable
radioactivity as described in Materials and nethods.
c cycl was Omitted from control experiments
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m n i n a r v N a l v e r i o n Of the 'X-XnTn
-bel.
ASF is used as FI model
protein for evaluating
residualiring labels because its
k m e t i c s Of
clearance from the circulation. its mechanism Of uDtake by heDatooYtes
:a1
Of

Unlabeled ASF increased the half-life Of *I-InTi-ASf t o greater than 0.5
h, consistent with saturetion Of the hepatocyte receptor for
galaCtOBeterminal glycoproteins and indicative that attachment of tI-InTn did not
interfere with clearance of ASP by this receptor-mediated pathway.
In
the absence of competitor,more than 901 of injected radioactivitv from
.I-I~T~-ASF was recovered in liverat 15 min after injection

TIME (days)

. Kinetics of whole body clearance of radioactivity from fetuin
( e ) or *I-InTn (A). Animals were injected
=with
*I ( 0 ) . '1-DLT
with 2.5 x 10' Epm (25-50 Y9) of labeled protein.
The tissue distribution Of radioactivity at 4 d after injlction Of
*I-InTn-MA. shown in Table 11, confirms previous evidence using*I-DLTRSA that catabolism o f RSA taker place primarily in muscle and s k i n ( 1 1 .

14127

Residualizing Labels: Inulin-'251-Tyramine

_
.
.
"""""...""""...."."""""""..""""..""""...""
_.."_..."_".."__".."""..."""..""""""..""".""
".
.
"
Table I 1 1
Table I1

Recovery Of radioactivity and distributlon of degradation products
in
tissue.. 4 days after injectLonof * I - I ~ T ~ - R Sm
A ratsa
""__..""_"."""""""..""".."""".""".""""""""
i acid-soluble
tprotein
Tissue
\cpm
recoy red
radioactivity
catabolized'
in body'
.""""""""""""""""..""".""""""""..""""""
. .
"".
"".
."" "".
67.8 z 4.9
25.6
Skln
37.8
2.9
RSF
*I-DLT
<0.01
0.31
2.3
30.9
1.7
51.9
4.e
16.0
nuscle
*I-lnTn
<0.01
0.136
5.1
10.4
6.6
6.1
Fat
9.1
2.0
5.6
Liver
7.5
0.2
14.9
1.4
2.1
0.2
75.7 f 0.9
1.8
*I-DLTFET
0.58
0.74
0.91
0.31
53
L,.29
2.5
Kidney
0.6
Spleen
0.8
0.2
78.4
0.7
*I-InTn
0.58
0.32
2.2
0.43
13
0.17
4.3
8iood
9.8
1.5
<I
__..""__...""__...""".."""".""""."""."""...
""".*I-DLT
.
RSA
0.31
0.70
1.0
0.12
38
0.21
1.0
a Animals were injected with 12 x lo6 cpm (-100 "91 'I-InTn-RSA.
+I-InTn
0.31
0.21
2.6
0.24
77
0.16
4.3
.................................................
Total and acid solubleradioactivity
in tissues were measured as
a original Model is described in Fig. 6.
Compartmental nodel.
desc ibed in laterials and nethods.
Data are expressed as means and Standard deviationr for three
described in tert. allows for partitloninq Of degradation products into
fast and slow release comoartments.
animals. Recovery
of radioactivity in the bady at 4 days was 73
1 1
The cons rant^
is'equivalent to the FCR of the protein.
Of in~ected dose. The
sum Of radioactivity recovered
in tissue5 and
excreta accounted for 9 1 t 5 t of injected dose. I&== than 1% of total
refer to
The constan;, '&' and the corresponding half-lifef;za2)
radioactivity vas recovered in toto in heart. lung. thymus. thyroid,
thekinetics
Of
reyeas.
of degradationproducts
cells, as
det m i n e d experimentally for ASF and by SCoPfit f o r FET and RSA.
bone.cand stomach and intestine and their contents.
The ConSLant. LIS, refers to the
rate of uptake of protein into the
was determined by multiplylng the
Percent protein catabolized
slow release compartment: klr is. one component of the totalFCR.
average i recovered dose (CO~UIPII 2) by the average I acid-soluble
e F represents the percent Of total protein catabolism shunted into
radioactivity (Column 3 ) for each tissue.
"_....""""..""""""""""""".""""""""""-"""- the ?I& release compartment.
It is determined as: Fs = kl,/k
The Constant
reledsek3gi and the corresponding half-lzfe re&;
to the
kinetics of
degradationDrOduCts
from the slow-release
xinetis ModelinD of P1 a s m P otein Cbtabolisn. The model shown
in Fig.
compartment. a16 determined by SCoPfit optimization.
6 was chosen as the Simplest three compartrnent model for describing the
.
.
"
"
"
"
_
_
_
.
.
"
"
"
"
"
.
.
"
"
"
"
.
.
"
"
"
"
"
"
"""""""""""~
This model treats a11 extrspathway Of catabolism Of p l a s m proteins.
cellular protein as a single pool and a s s m e 5 that the distribution Of
the protein between vascular and extravascular compartments exerts an
This
rate (FCR).
O v e r a l l . the fitted curves generated in the above analyses do not
insignlficant effect on its fractional catabolic
threeassumption is supported by the ObfeNation that the kinetics of Wholecorrelate well with exnerimental data. S u m e s t i n Q thatthe
body elimination o f radioactivity from *I-FET and *I-RSA (Figures 4 and
58) are linear from time of injection and extrapolate to
essentially
1008 a f injected dose at zero time. The FCR (k ) for these proteins can
be estimated from the slooe Of either the Yhole'bodY
clearance Curve for
*I-labeled protein or the linear phase Of the pldsma Clearance Curves
Thus, while the
kinet<cs Of release Of degradation products from the
using any o f the labels: the two methods yield identical reCYltS, i.e.,
bod" are oseudo-first order in "1 dose renainina" rFi7s. 4 and 581, the
the slopes are identical within experimental error (Cf. Fig. 51.
seGent1.i
model predicts some initial period during .which radiobstive
degradation products should aCCUmulatein the intracellulbr compartment.
Thus. as observed with both the dotted and dashed lines obtained in the
previous analyses, there should
be a lag phase in the release Of
In fact. however, the data
degradation products from the body while.
EXTRACELLULAR
for *I-DLT-RSA and *I-DLT-FET extrapolate nearly linearly (on e. semi-log
PROTEIN
plot) t o 100% of dose at zero time. while there is only a slight
kl
indication of a IaQ-Dhase
for release of *I-InTn-FET and *I-IDTn-RSA
,.
4,
58 and 7 ) .
Onepo96ibleexplanation
for this
praducte(Figs.
discrepancy is that residualiringlabels are not retained efficiently by
a11 cell types. and that some cells nay release degradation products
INTRACELLULAR
INTRACELLULAR
with
minrmal
kinetic
delay.
This
was considered unlikely,
however.
PROTEIN
DEGRADATION
because non-degradable compounds are known to residualire well in a11
PRODUCTS
cell types which have
been Studied thus far in vivo and
in vitro.
Relevantstudies
in vivo include thosedemonstrating
retention of
residualizing labels in hepatocytes using ASF as. carrier protein (2.3.24
and Fig 4 1 , hepatic non-parenchymal cells using RNase 8 and heat/k3
denatured albumin ( 2 . 2 4 1 , skin and muscle fibroblasts using RSA (11 and
aortic endothelial using lipoproteins
(26).
In addition, studies in
EXTRACELLULAR
vitro have shown that residualizing labels are retained efflciently in
DEGRADATION
fibroblasts (8.10) and in cardiac endothelial cell5 (unpublished
PRODUCTS
observationrl.
Finally. numerous studies have shown that "on-demradable
compounds, including &rose
127,281. cellobiose and
ficoll (21) and
poly-D-amino acids (29) accumulate
in macrophage 1ysosr)mes in vitro.
The Widespread pathology associated rlthvarious
lysosomal storage
ka
diseases also suggests that at least tkmporary accumulation of nondegradable materials is Characteristic of cellular metabolism.
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Basic kinetic model for CataboliSm
disposition of degradation products.

of p l a s m

proteins and

The differential equations used in the SCoP program t o define the
model in Fig. 6 are Straightfomdrd:
(11 d(PLl/dt
(2) dC/dt

I

=

-kl*(PLl.

kl*(PL)

-

k3*C, and

( 3 ) dE/dt = k *C:
where PL = intact tracer in the ex&acellular (plasma + lymph) space.

C
E

-

=

labeled catabolites in the intracellular compartment,and
labeled catabolites in excreta.

The Constants k
and k
since. based kn ?2uperim!bts

ore not used in the calculations for the model
with ASF (Fig. 3 1 , the rates Of dearadation

A Dossible exolanatlon for Door fit between between nodel and data
was sudgested by 'recent studies of Buktenica et al. (30) Who have
proposed that proteins
token into cells by fluid-phase endocytosis,
along with their degradationproducts, may be excreted from cells by two
distinct pathways, i.e. from rapid and slow release Compartments.
In
their Studies they demonstrated thata fraction Of degradation products
from *I-labeled proteins were released from cells lmouse Deritoneal
macrophages and biby hamster kidney fibroblasts1 with a half-life Of
5-10 mi", while another fraction was apparently trapped in a ly6060mal
compartment and released With a half-life Of 1-2 d in vitro.
These
Obse-ations
suggestedto
us thatdegradationproducts
containing
residualizing labels night also be partitioned in cells in vivo.
One
fraction might be released rapidly, explaining the absence Of a lag
phase 1" release of degradatlon products from the body. and another
fraction retained and reletsed slowly from the lysosonal compartment.
It can then be postulated that both of these routes are accessible to
a11 endocytosed proteins. and that differential residualiration would
result from differences in partitioning Of the degradation
products
between the twopathways.

As a test of this
hypothesis. the Original model (Fig. 61 was
modified t o a compartmental model which allowed for rapid release of a
fraction Of degradation products
from cells.
The equations
for the
model for RSA were modified as follows:
(1) d(PL)/dt = -klt*(PL),

(2) dC/dt

=

kl5*(PL)

-

k3**C, and

(3) dE/dt = kls*C + klf*(PL):

where kit is the total FCR for RSA (0.31 d - l l , k
and k l f represent the
fraction of total FCR occurring via the blow- ah8 fast-release E m p a r t the actual data POibts, but a more fundamental error is oppaGent insofar
as the shape of the curves does not fit the actual trend in the data.
similar results (graphsnot shown) Were obtained with data on whale body
clearance Of *I-DLT-FET and *I-InTn-FET. using a k1 ,value of 0.59,
estimated from the actual half-life Of *I-FET. as shown m Fig. 4.
A s an alternative approach

t o fitting the data, it was accepted
that release Of ASF degradation productsfrom liver might not be a good
model for predicting the half-life of degradation prOdUCtS in peripheral
tiBsUe6.
Thus. theSCoPfitprogram
was used t o obtained Optimized
values of
and k3. The FCR for RSA (kll was assigned an initial value
of 0.31 d-f? with D range of 0.31-0.39 d , >.e., a half-life of
1.8-2.2 d. the observed range for the half-life of RSA in our laboratory
P 1 7 , 2 5 and Fig. 5). Initial values chosen for k were 0.30 and 0.136
for 'I-DLT
and *I-InTn, respectively. estikated as above from
studies with *I-DLT- SF and *I-InTn-ASF (Fig. 3); the allowed range for
k was 0.01-0.99.'-d
The dashed lines in Fig. 1 show the calculated
bist fit t o the data, Obtained using the RUnge-Kutta integrator routine
in the SCoPfit program.
Both of these lines also reveal a systematic
d e v i a t i m from the experimental
data, consistently Overshooting the
experimental data point5
at early timer and undershooting
at later
times. A s in the DrevioUS analvsis u d n a~.SCoP. similar discremancies
and systematic er&rs
Yere obtdined on optimizations with
da<a from
experiments with
*I-DLT-FET and *I-InTn-PET (graphs not shown).
The
resulting kinetic COnStants for the Optimilationr with both theRSR and
FET data are summarized in Table 111 (Original nodel).
In addition to
the poor fit to the data, the
optimized values Of k
are Of concern
since the corresponding
half-lives for loas Of *I%LT
and *I-InTn
degradation products fram the body (0.9-1.0 and 2.2-2.6 d. respectively)
are short, conpared t o Observed differences in residualiration Of
*I-DLT- and +I-InTn-labeled proteins
degradation products from 'I-.
(Fig. 4 and 58).

from experiments with
both *I-DLT-RSA and *I-InTn-RSA.
Equally good
fits (graphs not shown) were obtained for the experiments with *I-DLTFET and *I-InTn-FET (Fig. 4 ) . substituting the constant. 0.59 d-l for
0.11 d-l In the shove equations.
The estimated percent Of degradation
products released v i a the slow-release compartment and the
kinetic
Constant*
Corresponding half-lives
for retention
of
reridualiling*3siabJnsd Obtained
fromthe
several
experiments Were
internally consistent and reasonable.Thus,thethefraction
of
degradation prxluotr
shunted into the slaw release compartment
Table 111. Col. 7 ) increases from 38-53% for *I-DLT-labeled FET and(&
to 73-77% for the *I-lnTn-labeled prateins. Consistent with incraased
efficiency Of residualiration Of *I-InTn-labeled degradation products.
In addition. the values of kIS estimated with FET and RSI\ for *I-DLT and
*I-InTn degradation products are 2.5-3.0 and 4.3 d. respectively (Table
111, Co1. 91 and are in reasonable agreement with the 2.3 and 5 . 1 d
half-lives Observed for ASF degradation products in liver (Table
111,
Col. 4 , and Fig. 1).
While this model represents a11 cells involved in
the Catabolism Of RSA or FET as a Single compartment and as8ume9 that
the distribution Of degradation products between slow and fast release
compartments and their rates Of transportthrough the cell are identical
for all cell types. there is not a sufficient amount Of experimental
data with various proteins and labels to justify a more eophistisatsd
treatment at this time. However, the internal consistency and reasonableness Of the Linetic constants
obtalned from the optimization. as
well as the quality Of the fit to experimental data for both FET and
RSA, lend some support to the compartmentalmodel and justify continued
experimentation t o test the model in vivo and i n simpler model systems
in vitro.

